133 related articles for article (PubMed ID: 29282305)
1. Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models.
Almholt K; Hebsgaard JB; Nansen A; Andersson C; Pass J; Rønø B; Thygesen P; Pelzer H; Loftager M; Lund IK; Høyer-Hansen G; Frisch T; Jensen CH; Otte KS; Søe NH; Bartels EM; Andersen M; Bliddal H; Usher PA
J Immunol; 2018 Feb; 200(3):957-965. PubMed ID: 29282305
[TBL] [Abstract][Full Text] [Related]
2. Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.
Almholt K; Wang J; Pass J; Røder G; Padkjær SB; Hebsgaard JB; Xia W; Yang L; Forsell J; Breinholt VM; Thygesen P; Agersø H; Loftager M; Usher PA
J Mol Med (Berl); 2020 Apr; 98(4):585-593. PubMed ID: 32108909
[TBL] [Abstract][Full Text] [Related]
3. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M
Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634
[TBL] [Abstract][Full Text] [Related]
4. Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts.
Serratì S; Margheri F; Chillà A; Neumann E; Müller-Ladner U; Benucci M; Fibbi G; Del Rosso M
Arthritis Rheum; 2011 Sep; 63(9):2584-94. PubMed ID: 21547898
[TBL] [Abstract][Full Text] [Related]
5. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.
Toh ML; Bonnefoy JY; Accart N; Cochin S; Pohle S; Haegel H; De Meyer M; Zemmour C; Preville X; Guillen C; Thioudellet C; Ancian P; Lux A; Sehnert B; Nimmerjahn F; Voll RE; Schett G
Arthritis Rheumatol; 2014 Nov; 66(11):2989-3000. PubMed ID: 24623505
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Busso N; Péclat V; So A; Sappino AP
Ann Rheum Dis; 1997 Sep; 56(9):550-7. PubMed ID: 9370880
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.
Palmer G; Talabot-Ayer D; Lamacchia C; Toy D; Seemayer CA; Viatte S; Finckh A; Smith DE; Gabay C
Arthritis Rheum; 2009 Mar; 60(3):738-49. PubMed ID: 19248109
[TBL] [Abstract][Full Text] [Related]
8. uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action.
Dinesh P; Rasool M
Pharmacol Res; 2018 Aug; 134():31-39. PubMed ID: 29859810
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade.
Kaneko K; Williams RO; Dransfield DT; Nixon AE; Sandison A; Itoh Y
Arthritis Rheumatol; 2016 Feb; 68(2):521-31. PubMed ID: 26315469
[TBL] [Abstract][Full Text] [Related]
10. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
Pliyev BK; Antonova OA; Menshikov M
Mol Immunol; 2011 May; 48(9-10):1168-77. PubMed ID: 21470685
[TBL] [Abstract][Full Text] [Related]
11. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
12. Citrullination of synovial proteins in murine models of rheumatoid arthritis.
Vossenaar ER; Nijenhuis S; Helsen MM; van der Heijden A; Senshu T; van den Berg WB; van Venrooij WJ; Joosten LA
Arthritis Rheum; 2003 Sep; 48(9):2489-500. PubMed ID: 13130468
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Apparailly F; Bouquet C; Millet V; Noel D; Jacquet C; Opolon P; Perricaudet M; Sany J; Yeh P; Jorgensen C
Gene Ther; 2002 Feb; 9(3):192-200. PubMed ID: 11859422
[TBL] [Abstract][Full Text] [Related]
14. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching.
Semina E; Rubina K; Sysoeva V; Rysenkova K; Klimovich P; Plekhanova O; Tkachuk V
Eur J Cell Biol; 2016 Sep; 95(9):295-310. PubMed ID: 27324124
[TBL] [Abstract][Full Text] [Related]
15. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Li J; Ny A; Leonardsson G; Nandakumar KS; Holmdahl R; Ny T
Am J Pathol; 2005 Mar; 166(3):783-92. PubMed ID: 15743790
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Das A; Boyd N; Jones TR; Talarico N; McGuire PG
Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
[TBL] [Abstract][Full Text] [Related]
17. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
18. The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium.
Silverman MD; Haas CS; Rad AM; Arbab AS; Koch AE
Arthritis Rheum; 2007 Jun; 56(6):1817-26. PubMed ID: 17530710
[TBL] [Abstract][Full Text] [Related]
19. The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Buckley BJ; Ali U; Kelso MJ; Ranson M
Curr Drug Targets; 2019; 20(9):970-981. PubMed ID: 30516104
[TBL] [Abstract][Full Text] [Related]
20. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
Atkinson SM; Nansen A; Usher PA; Sondergaard BC; Mackay CR; Friedrichsen B; Chang CC; Tang R; Skov S; Haase C; Hornum L
Autoimmunity; 2015; 48(7):460-70. PubMed ID: 25915570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
